Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 3

Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

NCT07123467 · View on ClinicalTrials.gov ↗

Study Summary

This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with placebo.

Interventions

  • DRUG Low-Dose Cannabidiol
  • DRUG Placebo Matched to Moderate-Dose Cannabidiol
  • DRUG Moderate-Dose Cannabidiol
  • DRUG Placebo Matched to Low-Dose Cannabidiol

Study Locations (1)

Michigan

  • Wayne State University School of Medicine, Tolan Park Medical Building — Detroit

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-11-03
Est. Completion 2027-08-31
Phase Phase 3

Sponsor

Wayne State University

145 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07123467

The ClinicalTrials.gov registry entry for NCT07123467 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wayne State University, which has 145 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 4 interventions — of which Low-Dose Cannabidiol is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07123467 reports 1 study location spanning 1 distinct geographic area — top geographies include Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07123467 about?

NCT07123467 is a clinical study titled "Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder". This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cann...

What is the current status of trial NCT07123467?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2025-11-03. Estimated completion is 2027-08-31.

What conditions does trial NCT07123467 study?

This clinical trial studies the following conditions: Anxiety Disorders, Generalized Anxiety Disorder (GAD). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07123467?

The interventions under investigation include: Low-Dose Cannabidiol (DRUG), Placebo Matched to Moderate-Dose Cannabidiol (DRUG), Moderate-Dose Cannabidiol (DRUG), Placebo Matched to Low-Dose Cannabidiol (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07123467?

This trial is sponsored by Wayne State University, which has 145 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07123467 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial